AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $889,642 | +26.0% | 62,695 | +8.0% | 0.03% | +11.1% |
| Q3 2023 | $706,033 | +40.5% | 58,062 | +45.1% | 0.03% | +50.0% |
| Q2 2023 | $502,563 | +13.3% | 40,013 | 0.0% | 0.02% | +5.9% |
| Q1 2023 | $443,744 | +95124.0% | 40,013 | +4.8% | 0.02% | -10.5% |
| Q4 2022 | $466 | -99.9% | 38,175 | 0.0% | 0.02% | +5.6% |
| Q3 2022 | $399,000 | -7.2% | 38,175 | -4.6% | 0.02% | 0.0% |
| Q2 2022 | $430,000 | +13.5% | 40,026 | -0.1% | 0.02% | +38.5% |
| Q1 2022 | $379,000 | -18.1% | 40,053 | 0.0% | 0.01% | -13.3% |
| Q4 2021 | $463,000 | +30.1% | 40,053 | +7.6% | 0.02% | +15.4% |
| Q3 2021 | $356,000 | -1.4% | 37,226 | -0.7% | 0.01% | 0.0% |
| Q2 2021 | $361,000 | -20.1% | 37,480 | +17.0% | 0.01% | -38.1% |
| Q3 2020 | $452,000 | -38.1% | 32,037 | -33.8% | 0.02% | -43.2% |
| Q2 2020 | $730,000 | – | 48,409 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |